Literature DB >> 8734014

Mifepristone: antineoplastic studies.

O Sartor1, W D Figg.   

Abstract

Entities:  

Keywords:  Antimetabolites; Biology; Breast Cancer--prevention and control; Cancer; Diseases; Endocrine System; Hormone Antagonists; Hormone Receptors; Hormones; Membrane Proteins; Metabolic Effects; Neoplasms; Physiology; Ru-486--administraction and dosage; Ru-486--therapeutic use; Treatment

Mesh：

Substances：

Year:  1996        PMID： 8734014     DOI： 10.1097/00003081-199606000-00023

Source DB:  PubMed          Journal:  Clin Obstet Gynecol        ISSN： 0009-9201            Impact factor:   2.190


× No keyword cloud information.
  5 in total

1.  Glucocorticoid receptor antagonist sensitizes TRAIL-induced apoptosis in renal carcinoma cells through up-regulation of DR5 and down-regulation of c-FLIP(L) and Bcl-2.

Authors:  Kyoung-Jin Min; Ji Hoon Jang; Jung Tae Lee; Kyeong Sook Choi; Taeg Kyu Kwon
Journal:  J Mol Med (Berl)       Date:  2011-10-19       Impact factor: 4.599

2.  Antiglucocorticoid therapy for older adults with anxiety and co-occurring cognitive dysfunction: results from a pilot study with mifepristone.

Authors:  Eric J Lenze; Tamara Hershey; John W Newcomer; Jordan F Karp; Daniel Blumberger; Jennifer Anger; Peter Doré; David Dixon
Journal:  Int J Geriatr Psychiatry       Date:  2014-03-14       Impact factor: 3.485

3.  Phase I/II trial of the anti-HIV activity of mifepristone in HIV-infected subjects ACTG 5200.

Authors:  Michael F Para; Jeff Schouten; Susan L Rosenkranz; Song Yu; David Weiner; Pablo Tebas; C Jo White; Dominic Reeds; Juan Lertora; Kristine B Patterson; Eric S Daar; Winston Cavert; Barbara Brizz
Journal:  J Acquir Immune Defic Syndr       Date:  2010-04-01       Impact factor: 3.731

Review 4.  Antiprogestin pharmacodynamics, pharmacokinetics, and metabolism: implications for their long-term use.

Authors:  G R Jang; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1997-12

Review 5.  The prince and the pauper. A tale of anticancer targeted agents.

Authors:  Alfonso Dueñas-González; Patricia García-López; Luis Alonso Herrera; Jose Luis Medina-Franco; Aurora González-Fierro; Myrna Candelaria
Journal:  Mol Cancer       Date:  2008-10-23       Impact factor: 27.401
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.